Sultamicillin

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

Hartmut Lode - One of the best experts on this subject based on the ideXlab platform.

  • rational antibiotic therapy and the position of ampicillin sulbactam
    International Journal of Antimicrobial Agents, 2008
    Co-Authors: Hartmut Lode
    Abstract:

    In the current context of increasing antimicrobial resistance, it is important to use antibiotics rationally and to re-assess regularly the clinical usefulness of commonly used agents. This review focuses on the efficacy of the β-lactam ampicillin co-administered with the β-lactamase inhibitor sulbactam, either parenterally (ampicillin/sulbactam) or orally (Sultamicillin), for the treatment of bacterial infections. Clinical findings from the past decade confirm the results of numerous older studies and together provide good evidence to support the continued use of ampicillin/sulbactam and Sultamicillin in hospital- and community-acquired infections both in adults and children. This is also recognised in recent published national and international guidelines, many of which recommend ampicillin/sulbactam as first-line therapy for various respiratory and skin infections.

  • role of Sultamicillin and ampicillin sulbactam in the treatment of upper and lower bacterial respiratory tract infections
    International Journal of Antimicrobial Agents, 2001
    Co-Authors: Hartmut Lode
    Abstract:

    The emergence of β-lactamase-mediated resistance to β-lactam antibiotics among key respiratory tract pathogens has threatened the usefulness of the β-lactam agents familiar to physicians as being clinically effective and well tolerated. This article reassesses the clinical usefulness of ampicillin when administered in combination with the β-lactamase inhibitor sulbactam, either intravenously or orally (as the mutual prodrug Sultamicillin), in the treatment of upper and lower respiratory tract infections. Numerous clinical studies and several meta-analyses indicate that ampicillin/sulbactam and Sultamicillin are clinically effective and well tolerated in both adults and children, in agreement with published North American and European guidelines.

P Fall - One of the best experts on this subject based on the ideXlab platform.

  • comparative study of Sultamicillin and amoxicillin clavulanate treatment of acute otitis media
    Pediatric Infectious Disease Journal, 1993
    Co-Authors: Kenny H Chan, Charles D Bluestone, Ling Shi Tan, Kieth S Reisinger, Mark M Blatter, P Fall
    Abstract:

    Abstract Sultamicillin is a mutual prodrug of ampicillin and sulbactam that is chemically linked by a diester bond. This investigational agent has beta-lactamase-inhibiting activity by virtue of sulbactam, a novel beta-lactamase inhibitor. A double blind randomized study was conducted to evaluate the safety, efficacy and tolerance of Sultamicillin for treatment of acute otitis media compared with amoxicillin-clavulanate. A total of 144 subjects were included (96 randomly assigned to the Sultamicillin and 48 to the amoxicillin-clavulanate groups). No safety concerns for Sultamicillin were identified during the study. The clinical efficacy in effusion clearance between the two groups was found not to be statistically different at 10 days (P = 0.23) and 30 days (P = 0.72). Similar rates of side effects, primarily gastrointestinal, were reported in both study groups. Sultamicillin may be an alternative for the treatment of acute otitis media when persistence and recurrence of disease become an issue.

Mocellin M. - One of the best experts on this subject based on the ideXlab platform.

  • Efficacy And Safety Of Sultamicillin (ampicillin/sulbactan) And Amoxicillin/clavulanic Acid In The Treatment Of Upper Respiratory Tract Infections In Adults - An Open-label, Multicentric, Randomized Trial [eficácia E Segurança De Sultamicilina (ampicilina/sulbactam) E Amoxacilina/clavulanato No Tratamento Das Infecções De Via Aéreas Superiores Em Adultos - Um Estudo Multicêntrico, Aberto E Randomizado]
    2015
    Co-Authors: Ferreira J.b., Rapoport P.b., Sakano E., Kos A.o.d.a., Piltcher O.b., Pignatari S.s.n., Pinheiro S.d., Mocellin M.
    Abstract:

    Upper respiratory tract infections are the most common causes of medical visits in children and adults, demanding massive use of antibiotics. Bacterial resistance caused by beta-lactamase is one of the most serious problems in this matter. Sultamicillin, a double pro-drug of Ampicillin/Sulbactan, is a potent beta-lactamase inhibitor which can face this challenge. Aim: evaluate efficacy, safety and tolerability of Ampicillin/Sulbactan compared to Amoxicillin/ Clavulanate in upper respiratory tract infections in adults. Methods: 102 patients were enrolled and randomized to receive Ampicillin/Sulbactan or Amoxicillin/Clavulanate during 10 days. They were evaluated 10 and 30 days after treatment to learn about the therapeutic response. Results: There were no differences between the two groups respecting cure at the end of treatment (visit 2) or at the end of the study (visit 3). Cure ratio was 61.7% and 93.2% (visits 2 and 3) in the Amoxicillin/Clavulanate group compared to 64.4% and 97.4%, respectively, in Ampicillin/Sulbactan group. The adverse events ratio for the two groups was the same (p=0.940). The number of patients with diarrhea was greater in the group of patients receiving Amoxicillin/Clavulanate (70.6%) than in the group receiving Ampicillin/Sulbactan (29.4%) (p=0.0164). Conclusions: Ampicillin/Sulbactan is as safe and efficient as Amoxicillin/Clavulanate in the empiric treatment of upper respiratory infections in adults. The low occurrence of diarrhea in the group receiving Ampicillin/Sulbactan needs confirmation in other studies.721104111Diagnosis and management of acute otitis media (2004) Pediatrics, 113 (5), pp. 1451-1465Snow, V., Mottur-Pilson, C., Cooper, R.J., Hoffman, J.R., Principles of appropriate antibiotic use for acute pharyngitis in adults (2001) Ann Intern Med, 134 (6), pp. 506-508Snow, V., Mottur-Pilson, C., Hickner, J.M., Principles of appropriate antibiotic use for acute sinusitis in adults (2001) Ann Intern Med, 134 (6), pp. 495-497Snow, V., Mottur-Pilson, C., Gonzales, R., Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections in adults (2001) Ann Intern Med, 134 (6), pp. 487-489Rosenfeld, R.M., Otitis, antibiotics, and the greater good (2004) Pediatrics, 114 (5), pp. 1333-1335Webb, K.H., Needham, C.A., Kurtz, S.R., Use of a high-sensitivity rapid strep test without culture confirmation of negative results2 years' experience (2000) J Fam Pract, 49 (1), pp. 34-38Needham, C.A., McPherson, K.A., Webb, K.H., Streptococcal pharyngitisimpact of a high-sensitivity antigen test on physician outcome (1998) J Clin Microbiol, 36 (12), pp. 3468-3473Webb, K.H., Does culture confirmation of high-sensitivity rapid streptococcal tests make sense? a medical decision analysis (1998) Pediatrics, 101 (2), pp. E2Pitrez, P.M., Pitrez, J.L., Acute upper respiratory tract infectionsoutpatient diagnosis and treatment (2003) J Pediatr, 79 (1 SUPPL.), pp. S77-S86. , Rio JTalan, D.A., Moran, G.J., Pinner, R.W., Progress toward eliminating Haemophilus influenzae type b disease among infants and children - United States, 1987-1997 (1999) Ann Emerg Med, 34 (1), pp. 109-111O'Brien, T.F., Resistance of bacteria to antibacterial agentsreport of task force 2 (1987) Rev Infect Dis, (3 SUPPL.), pp. S244Moosdeen, F., Keeble, J., Williams, J.D., Induction/inhibition of chromosomal b-lactamases by b-lactamase inhibitors (1986) Rev Infect Dis, 8 (5), pp. S562-S568Acar, J.F., Gutmann, L., Kitzis, M.D., Beta-lactamases in clinical isolates Spectrum implications of sulbactam/ampicillin (1988) Drugs, 35 (7 SUPPL.), pp. 12-16Jones, R.N., Dudley, M.N., Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactamanalysis of the correlations between in vitro test results and clinical response (1997) Diagn Microbiol Infect Dis, 28 (1), pp. 5-18Lode, H., Role of Sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections (2001) Int J Antimicrob Agents, 18 (3), pp. 199-209Bello, H., Dominguez, M., Gonzalez, G., Zemelman, R., Mella, S., Young, H.K., In vitro activities of ampicillin, sulbactam and a combination of ampicillin and sulbactam against isolates of Acinetobacter calcoaceticus- Acinetobacter baumannii complex isolated in Chile between 1990 and 1998 (2000) J Antimicrob Chemother, 45 (5), pp. 712-713Cisterna, R., Fresnadillo, M.J., Garcia-Rodriguez, J.A., Gobernado, M., Martin, R., Perea, E., Ampicillin-sulbactam activity against respiratory isolates of Haemophilus influenzae (1998) Rev Esp Quimioter, 11 (3), pp. 245-250Okimoto, N., Kurihara, T., Honda, N., Asaoka, N., Fujita, K., Ohba, H., Clinical effect of ampicillin with beta-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly (2003) J Infect Chemother, 9 (2), pp. 183-186Alpuche-Aranda, C.M., Beta-lactamase production and the role of ampicillin/sulbactam (1998) Pediatr Infect Dis J, 17 (3 SUPPL.), pp. S8-11Arredondo-Garcia, J.L., Use of ampicillin/sulbactam (Sultamicillin) in the management of pediatric infections. Introduction (1998) Pediatr Infect Dis J, 17 (3 SUPPL.), pp. S3Lopez, E.L., Rivas, N.A., Clinical use of Sultamicillin (ampicillin/sulbactam) in children (1998) Pediatr Infect Dis J, 17 (3 SUPPL.), pp. S12-S14Adam, D., Beta-lactam antibioticstheir role in the management of infections in children (1998) Pediatr Infect Dis J, 17 (3 SUPPL.), pp. S4-S7Kanra, G., Experience with ampicillin/sulbactam in severe infections (2002) J Int Med Res, 30 (1 SUPPL.), pp. 20A-30AAdam, D., Beta-lactam/beta-lactamase inhibitor combinations in empiric management of pediatric infections (2002) J Int Med Res, 30 (1 SUPPL.), pp. 10A-19AZhu, X.L., Wong, W.K., Yeung, W.M., Mo, P., Tsang, C.S., Pang, K.H., A randomized, double-blind comparison of ampicillin/sulbactam and ceftriaxone in the prevention of surgical-site infections after neurosurgery (2001) Clin Ther, 23 (8), pp. 1281-1291Allewelt, M., Schuler, P., Bolcskei, P.L., Mauch, H., Lode, H., Ampicillin + sulbactam vs clindamycin +/- cephalosporin for the treatment of aspiration pneumonia and primary lung abscess (2004) Clin Microbiol Infect, 10 (2), pp. 163-170Geckler, R., A comparison of ampicillin/sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract (1994) Clin Ther, 16, pp. 662-672Weigelt, J.A., A comparison of ampicillin/sulbactam and cefoxitin in the treatment of bacterial skin and skin-structure infections (1994) Adv Ther, 11, pp. 183-191Bluestone, C.D., Role of sulbactam/ampicillin in the treatment of bacterial infections of the upper respiratory tract of children (1987) "SulbactamWorldwide Clinical Experience", 15th International Congress of Chemotherapy, , Istanbul, Turkey, July 21Gilbert, D.N., Moellering Jr., R.C., Sande, M.A., The Sanford "Guia para Terapêutica Antimicrobiana" 33 a Edição 2003/2004 Em Português, , EPUC. São Paul

  • Efficacy And Safety Of Sultamicillin (ampicillin/sulbactan) And Amoxicillin/clavulanic Acid In The Treatment Of Upper Respiratory Tract Infections In Adults - An Open-label, Multicentric, Randomized Trial [eficácia E Segurança De Sultamicilina (ampicilina/sulbactam) E Amoxacilina/clavulanato No Tratamento Das Infecções De Via Aéreas Superiores Em Adultos - Um Estudo Multicêntrico, Aberto E Randomizado]
    2015
    Co-Authors: Ferreira J.b., Rapoport P.b., Sakano E., Kos A.o.d.a., Piltcher O.b., Pignatari S.s.n., Pinheiro S.d., Mocellin M.
    Abstract:

    Upper respiratory tract infections are the most common causes of medical visits in children and adults, demanding massive use of antibiotics. Bacterial resistance caused by beta-lactamase is one of the most serious problems in this matter. Sultamicillin, a double pro-drug of Ampicillin/Sulbactan, is a potent beta-lactamase inhibitor which can face this challenge. Aim: evaluate efficacy, safety and tolerability of Ampicillin/Sulbactan compared to Amoxicillin/ Clavulanate in upper respiratory tract infections in adults. Methods: 102 patients were enrolled and randomized to receive Ampicillin/Sulbactan or Amoxicillin/Clavulanate during 10 days. They were evaluated 10 and 30 days after treatment to learn about the therapeutic response. Results: There were no differences between the two groups respecting cure at the end of treatment (visit 2) or at the end of the study (visit 3). Cure ratio was 61.7% and 93.2% (visits 2 and 3) in the Amoxicillin/Clavulanate group compared to 64.4% and 97.4%, respectively, in Ampicillin/Sulbactan group. The adverse events ratio for the two groups was the same (p=0.940). The number of patients with diarrhea was greater in the group of patients receiving Amoxicillin/Clavulanate (70.6%) than in the group receiving Ampicillin/Sulbactan (29.4%) (p=0.0164). Conclusions: Ampicillin/Sulbactan is as safe and efficient as Amoxicillin/Clavulanate in the empiric treatment of upper respiratory infections in adults. The low occurrence of diarrhea in the group receiving Ampicillin/Sulbactan needs confirmation in other studies

Kenny H Chan - One of the best experts on this subject based on the ideXlab platform.

  • comparative study of Sultamicillin and amoxicillin clavulanate treatment of acute otitis media
    Pediatric Infectious Disease Journal, 1993
    Co-Authors: Kenny H Chan, Charles D Bluestone, Ling Shi Tan, Kieth S Reisinger, Mark M Blatter, P Fall
    Abstract:

    Abstract Sultamicillin is a mutual prodrug of ampicillin and sulbactam that is chemically linked by a diester bond. This investigational agent has beta-lactamase-inhibiting activity by virtue of sulbactam, a novel beta-lactamase inhibitor. A double blind randomized study was conducted to evaluate the safety, efficacy and tolerance of Sultamicillin for treatment of acute otitis media compared with amoxicillin-clavulanate. A total of 144 subjects were included (96 randomly assigned to the Sultamicillin and 48 to the amoxicillin-clavulanate groups). No safety concerns for Sultamicillin were identified during the study. The clinical efficacy in effusion clearance between the two groups was found not to be statistically different at 10 days (P = 0.23) and 30 days (P = 0.72). Similar rates of side effects, primarily gastrointestinal, were reported in both study groups. Sultamicillin may be an alternative for the treatment of acute otitis media when persistence and recurrence of disease become an issue.

Ferreira J.b. - One of the best experts on this subject based on the ideXlab platform.

  • Efficacy And Safety Of Sultamicillin (ampicillin/sulbactan) And Amoxicillin/clavulanic Acid In The Treatment Of Upper Respiratory Tract Infections In Adults - An Open-label, Multicentric, Randomized Trial [eficácia E Segurança De Sultamicilina (ampicilina/sulbactam) E Amoxacilina/clavulanato No Tratamento Das Infecções De Via Aéreas Superiores Em Adultos - Um Estudo Multicêntrico, Aberto E Randomizado]
    2015
    Co-Authors: Ferreira J.b., Rapoport P.b., Sakano E., Kos A.o.d.a., Piltcher O.b., Pignatari S.s.n., Pinheiro S.d., Mocellin M.
    Abstract:

    Upper respiratory tract infections are the most common causes of medical visits in children and adults, demanding massive use of antibiotics. Bacterial resistance caused by beta-lactamase is one of the most serious problems in this matter. Sultamicillin, a double pro-drug of Ampicillin/Sulbactan, is a potent beta-lactamase inhibitor which can face this challenge. Aim: evaluate efficacy, safety and tolerability of Ampicillin/Sulbactan compared to Amoxicillin/ Clavulanate in upper respiratory tract infections in adults. Methods: 102 patients were enrolled and randomized to receive Ampicillin/Sulbactan or Amoxicillin/Clavulanate during 10 days. They were evaluated 10 and 30 days after treatment to learn about the therapeutic response. Results: There were no differences between the two groups respecting cure at the end of treatment (visit 2) or at the end of the study (visit 3). Cure ratio was 61.7% and 93.2% (visits 2 and 3) in the Amoxicillin/Clavulanate group compared to 64.4% and 97.4%, respectively, in Ampicillin/Sulbactan group. The adverse events ratio for the two groups was the same (p=0.940). The number of patients with diarrhea was greater in the group of patients receiving Amoxicillin/Clavulanate (70.6%) than in the group receiving Ampicillin/Sulbactan (29.4%) (p=0.0164). Conclusions: Ampicillin/Sulbactan is as safe and efficient as Amoxicillin/Clavulanate in the empiric treatment of upper respiratory infections in adults. The low occurrence of diarrhea in the group receiving Ampicillin/Sulbactan needs confirmation in other studies.721104111Diagnosis and management of acute otitis media (2004) Pediatrics, 113 (5), pp. 1451-1465Snow, V., Mottur-Pilson, C., Cooper, R.J., Hoffman, J.R., Principles of appropriate antibiotic use for acute pharyngitis in adults (2001) Ann Intern Med, 134 (6), pp. 506-508Snow, V., Mottur-Pilson, C., Hickner, J.M., Principles of appropriate antibiotic use for acute sinusitis in adults (2001) Ann Intern Med, 134 (6), pp. 495-497Snow, V., Mottur-Pilson, C., Gonzales, R., Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections in adults (2001) Ann Intern Med, 134 (6), pp. 487-489Rosenfeld, R.M., Otitis, antibiotics, and the greater good (2004) Pediatrics, 114 (5), pp. 1333-1335Webb, K.H., Needham, C.A., Kurtz, S.R., Use of a high-sensitivity rapid strep test without culture confirmation of negative results2 years' experience (2000) J Fam Pract, 49 (1), pp. 34-38Needham, C.A., McPherson, K.A., Webb, K.H., Streptococcal pharyngitisimpact of a high-sensitivity antigen test on physician outcome (1998) J Clin Microbiol, 36 (12), pp. 3468-3473Webb, K.H., Does culture confirmation of high-sensitivity rapid streptococcal tests make sense? a medical decision analysis (1998) Pediatrics, 101 (2), pp. E2Pitrez, P.M., Pitrez, J.L., Acute upper respiratory tract infectionsoutpatient diagnosis and treatment (2003) J Pediatr, 79 (1 SUPPL.), pp. S77-S86. , Rio JTalan, D.A., Moran, G.J., Pinner, R.W., Progress toward eliminating Haemophilus influenzae type b disease among infants and children - United States, 1987-1997 (1999) Ann Emerg Med, 34 (1), pp. 109-111O'Brien, T.F., Resistance of bacteria to antibacterial agentsreport of task force 2 (1987) Rev Infect Dis, (3 SUPPL.), pp. S244Moosdeen, F., Keeble, J., Williams, J.D., Induction/inhibition of chromosomal b-lactamases by b-lactamase inhibitors (1986) Rev Infect Dis, 8 (5), pp. S562-S568Acar, J.F., Gutmann, L., Kitzis, M.D., Beta-lactamases in clinical isolates Spectrum implications of sulbactam/ampicillin (1988) Drugs, 35 (7 SUPPL.), pp. 12-16Jones, R.N., Dudley, M.N., Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactamanalysis of the correlations between in vitro test results and clinical response (1997) Diagn Microbiol Infect Dis, 28 (1), pp. 5-18Lode, H., Role of Sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections (2001) Int J Antimicrob Agents, 18 (3), pp. 199-209Bello, H., Dominguez, M., Gonzalez, G., Zemelman, R., Mella, S., Young, H.K., In vitro activities of ampicillin, sulbactam and a combination of ampicillin and sulbactam against isolates of Acinetobacter calcoaceticus- Acinetobacter baumannii complex isolated in Chile between 1990 and 1998 (2000) J Antimicrob Chemother, 45 (5), pp. 712-713Cisterna, R., Fresnadillo, M.J., Garcia-Rodriguez, J.A., Gobernado, M., Martin, R., Perea, E., Ampicillin-sulbactam activity against respiratory isolates of Haemophilus influenzae (1998) Rev Esp Quimioter, 11 (3), pp. 245-250Okimoto, N., Kurihara, T., Honda, N., Asaoka, N., Fujita, K., Ohba, H., Clinical effect of ampicillin with beta-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly (2003) J Infect Chemother, 9 (2), pp. 183-186Alpuche-Aranda, C.M., Beta-lactamase production and the role of ampicillin/sulbactam (1998) Pediatr Infect Dis J, 17 (3 SUPPL.), pp. S8-11Arredondo-Garcia, J.L., Use of ampicillin/sulbactam (Sultamicillin) in the management of pediatric infections. Introduction (1998) Pediatr Infect Dis J, 17 (3 SUPPL.), pp. S3Lopez, E.L., Rivas, N.A., Clinical use of Sultamicillin (ampicillin/sulbactam) in children (1998) Pediatr Infect Dis J, 17 (3 SUPPL.), pp. S12-S14Adam, D., Beta-lactam antibioticstheir role in the management of infections in children (1998) Pediatr Infect Dis J, 17 (3 SUPPL.), pp. S4-S7Kanra, G., Experience with ampicillin/sulbactam in severe infections (2002) J Int Med Res, 30 (1 SUPPL.), pp. 20A-30AAdam, D., Beta-lactam/beta-lactamase inhibitor combinations in empiric management of pediatric infections (2002) J Int Med Res, 30 (1 SUPPL.), pp. 10A-19AZhu, X.L., Wong, W.K., Yeung, W.M., Mo, P., Tsang, C.S., Pang, K.H., A randomized, double-blind comparison of ampicillin/sulbactam and ceftriaxone in the prevention of surgical-site infections after neurosurgery (2001) Clin Ther, 23 (8), pp. 1281-1291Allewelt, M., Schuler, P., Bolcskei, P.L., Mauch, H., Lode, H., Ampicillin + sulbactam vs clindamycin +/- cephalosporin for the treatment of aspiration pneumonia and primary lung abscess (2004) Clin Microbiol Infect, 10 (2), pp. 163-170Geckler, R., A comparison of ampicillin/sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract (1994) Clin Ther, 16, pp. 662-672Weigelt, J.A., A comparison of ampicillin/sulbactam and cefoxitin in the treatment of bacterial skin and skin-structure infections (1994) Adv Ther, 11, pp. 183-191Bluestone, C.D., Role of sulbactam/ampicillin in the treatment of bacterial infections of the upper respiratory tract of children (1987) "SulbactamWorldwide Clinical Experience", 15th International Congress of Chemotherapy, , Istanbul, Turkey, July 21Gilbert, D.N., Moellering Jr., R.C., Sande, M.A., The Sanford "Guia para Terapêutica Antimicrobiana" 33 a Edição 2003/2004 Em Português, , EPUC. São Paul

  • Efficacy And Safety Of Sultamicillin (ampicillin/sulbactan) And Amoxicillin/clavulanic Acid In The Treatment Of Upper Respiratory Tract Infections In Adults - An Open-label, Multicentric, Randomized Trial [eficácia E Segurança De Sultamicilina (ampicilina/sulbactam) E Amoxacilina/clavulanato No Tratamento Das Infecções De Via Aéreas Superiores Em Adultos - Um Estudo Multicêntrico, Aberto E Randomizado]
    2015
    Co-Authors: Ferreira J.b., Rapoport P.b., Sakano E., Kos A.o.d.a., Piltcher O.b., Pignatari S.s.n., Pinheiro S.d., Mocellin M.
    Abstract:

    Upper respiratory tract infections are the most common causes of medical visits in children and adults, demanding massive use of antibiotics. Bacterial resistance caused by beta-lactamase is one of the most serious problems in this matter. Sultamicillin, a double pro-drug of Ampicillin/Sulbactan, is a potent beta-lactamase inhibitor which can face this challenge. Aim: evaluate efficacy, safety and tolerability of Ampicillin/Sulbactan compared to Amoxicillin/ Clavulanate in upper respiratory tract infections in adults. Methods: 102 patients were enrolled and randomized to receive Ampicillin/Sulbactan or Amoxicillin/Clavulanate during 10 days. They were evaluated 10 and 30 days after treatment to learn about the therapeutic response. Results: There were no differences between the two groups respecting cure at the end of treatment (visit 2) or at the end of the study (visit 3). Cure ratio was 61.7% and 93.2% (visits 2 and 3) in the Amoxicillin/Clavulanate group compared to 64.4% and 97.4%, respectively, in Ampicillin/Sulbactan group. The adverse events ratio for the two groups was the same (p=0.940). The number of patients with diarrhea was greater in the group of patients receiving Amoxicillin/Clavulanate (70.6%) than in the group receiving Ampicillin/Sulbactan (29.4%) (p=0.0164). Conclusions: Ampicillin/Sulbactan is as safe and efficient as Amoxicillin/Clavulanate in the empiric treatment of upper respiratory infections in adults. The low occurrence of diarrhea in the group receiving Ampicillin/Sulbactan needs confirmation in other studies

Related terms

Sultamicillin - 15 days free trial to Access Experts & Abstracts